Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

I multiple-dose HCV trial were presented that showed bavituximab was well tolerated and demonstrated encouraging signs of anti-viral activity.

Cotara(R) Brain Cancer Clinical Program

To help accelerate the ongoing Phase II trial of Cotara in patients with glioblastoma multiforme, one of the most deadly forms of brain cancer, Peregrine recently added two new sites to the study, for a total of seven clinical sites now actively screening and recruiting patients. In addition, Peregrine regained operational responsibility for the ongoing Cotara dosimetry and dose confirmation clinical study and is working closely with the participating academic medical centers to complete patient enrollment and dosing during 2008. Positive results from these two clinical trials are expected to pave the way for Phase III product registration trials for Cotara.

Mr. King concluded, "In 2008 we plan to conduct a number of mid-phase trials for our lead clinical programs, each of which has significant clinical and commercial potential. We have long maintained that positive Phase II clinical data would be the keys to building sustainable shareholder value in the company, and we are optimistic that Peregrine will be able to begin delivering on that promise in the upcoming year."

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional informatio
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...I, Nov. 24 /PRNewswire-Asia/ -- NOD Pharmaceutical...ice (PTO) has allowed the patent application for,i..., NOD technology is a highly efficient ap...o-adhesive nano-particles to enable oral delivery ... technology is a platform technology,that can be a...
(Date:11/24/2009)...24 Blue Marble Energy Corp. announ...evelopment Authority (OPDA) were recently awarded ...c Revitalization Board (CERB) in a private/public ...ty biochemical biorefinery in Lincoln County, WA. ...the development of our biorefinery and bring over ...
(Date:11/24/2009)...HTL , TORONTO, Nov. 24 /PRNewswire-FirstCall/...otto Capital Inc., a leading provider of advanced ...search and fertility clinic markets, today reporte...quarter ended September 30, 2009. , , Q3 2009 ...ared with $1.43 million in Q3 2008, - Gross p...
(Date:11/24/2009)..., Calif., Nov. 24 Genomi...at Randy Scott, Genomic Health,s Executive Chairma...ealth Care Conference in New York City on Tuesday,...ss the live and subsequently archived webcast of t...ion of Genomic Health,s website at http://investo...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10Genomic Health to Present at Piper Jaffray Health Care Conference 2
... One of the ways we defend ourselves against bact... metals they crave. A multi-disciplinary team led ...covered that a protein inside certain immune syste...ping up manganese and zinc. , The findings, report...ding metals to starve bacteria is a viable thera...
...igma-Aldrich and Atlas Antibodies Establish Exclus...nership, ST. LOUIS, Feb. 14 Sigma-Aldrich (Nasda...with Atlas Antibodies to,distribute Prestige Antib...rce -- to the proteomics and cell biology research...ies, the library is expected to grow by,several th...
...Countless Patients Cannot Afford Life-Saving Bioph...s campaign,to enact meaningful biogenerics legisla...of safe and effective biogenerics, CCPM unveiled a... in the snow stating: "Don,t Leave,Patients Out in...generics legislation should be,balanced to foster ...
Other Biology Technology:Immune system protein starves 'staph' bacteria 2Immune system protein starves 'staph' bacteria 3Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers 2Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers 3
(Date:11/24/2009)... Lupus Research Institute (LRI) today named 12 new...3.6 million, recognize innovative work across a br...for their creativity, novelty, and potential to dr...eat, and cure the complex disease of systemic lupu...hed lupus researchers across the nation and includ...
(Date:11/24/2009)...nts that keep weakened and flabby arteries from co... months, those stents are no longer needed -- once...ssary. Previously, doctors had no choice but to le...el Aviv University,s Department of Biomedical Engi...latform that carries drugs where they,re needed, t...
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The W... a report revealing that the last remaining popula...icantly due to the rising tide of poaching and hab...l help inform Russian officials of what needs to b...ld,s biggest cat. , The report was ...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A coating for life 2Report shows dramatic decline in Siberian tigers 2Social isolation worsens cancer 58473 1Social isolation worsens cancer 58473 2Young adults may outgrow bipolar disorder 58470 1Young adults may outgrow bipolar disorder 58470 2How the 100th protein structure solved at Diamond impacts our understanding of how insects smell 10164 1How the 100th protein structure solved at Diamond impacts our understanding of how insects smell 10164 2How the 100th protein structure solved at Diamond impacts our understanding of how insects smell 10164 3
...BRIDGE, Mass. (Dec. 15, 2008) Infants and adults ... typically have a poor prognosis, and most infants...are varying causes of MLL, most cases are caused b.... , When the MLL gene is fused to the AF4 gene...hough researchers have known that the MLL-AF4 prot...
... YORK (Dec. 15, 2008) Using stem cell lines not t...ity Medical Center have designed a new way to "gro...ter angiogenesis a physiological process involvin...g vessels has been a major roadblock in tissue re...use of angiogenic growth factors and the fabricati...
...TON [Dec. 15, 2008] Three-quarters of youths wit...levels of vitamin D, according to a study by resea...t suggest children with the disease may need vitam...er in life. , "To our surprise, we found extremel...affel, M.D., M.P.H., Chief of the Pediatric, Adole...
Other Biology News:Tracking the molecular pathway to mixed-lineage leukemia 2Columbia University scientist devises new way to more rapidly generate bone tissue 2Joslin research finds nearly three-quarters of youths with diabetes insufficient in vitamin D 2
...roughput, water bath thermal cycler capable of the...This equates to 9,216 reactions per run when using...rs a basket of plates between three water baths re...iderably faster than those of peltier block cycler...
...ideoxycytidine is a cytidine analog that has been ...ivity. Immunogen: Chemical / Small Molecule con... the ddC antiserum was determined by calculating t...g at the 50% intercept of the respective dose resp...
MSC.12 class II safety cabinet (Type A1) - CE Marked (230V / 50Hz) from Thermo Scientific
...ariety of motion options - roller, shaker, orbital...d rotate motions!,, Two independently oper...tting procedures requiring different settings, tem...oller action to operate a shaker tray (included) ,...
Biology Products: